Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Why Are These Four Stocks Surging Amid Today’s Market Slump?

FireEye Inc (NASDAQ:FEYE)’s stock jumped today, as the stock was upgraded by Citigroup to Buy’ from ‘Neutral’. According to Citi’s Walter Pritchard, cited by Barron’s, the company can maintain its position in the market and has shown significant strength compared to its competitors. He also feels shares are trading at a significant discount and has thus increased the price target to $35 per share. Market participants were quick to pounce, with FireEye Inc (NASDAQ:FEYE) rallying by 8.5% during the first hour of trading.

Follow Fireeye Inc. (NASDAQ:FEYE)
Trade (NASDAQ:FEYE) Now!

During the third quarter, FireEye Inc (NASDAQ:FEYE) has gained the attention of a couple more hedge funds, with 37 elite investors reporting a long position in the company. Still, their holdings account for just 7.1% of the company’s common stock. The largest position among the funds Insider Monkey follows is held by Karthik Sarma and SRS Investment Management. In its latest 13F filing, the fund reported ownership of 4.47 million shares, up by 36% during the quarter and valued at $142 million.

TherapeuticsMD Inc (NYSEMKT:TXMD)’s stock has skyrocketed this morning by as much as 50% after the company announced positive Phase 3 results for one of its drug candidates. A developer of women’s healthcare products, TherapeuticsMD has been testing TX-004HR, a softgel designed to address dyspareunia, a symptom of vulvar and vaginal atrophy (VVA) due to menopause. Roughly one half of women in the United States are affected by this condition, which has a significantly negative impact on their quality of life.

“With efficacy observed as early as two weeks and the convenience of the applicator-free vaginal softgel, we believe that, if approved, TX-004HR has the potential to offer a highly differentiated, new treatment option that meets the needs of the millions of postmenopausal women with VVA who are suffering from pain during sexual intercourse,” said Robert G. Finizio, the CEO of TherapeuticsMD.

Follow Therapeuticsmd Inc. (NYSEMKT:TXMD)
Trade (NYSEMKT:TXMD) Now!

Key managers have queued up to dump TherapeuticsMD Inc (NYSEMKT:TXMD)’s stock during the third quarter, although in the end the number of hedge fund invested in the stock remained the same at 13. Israel Englander sold nearly a quarter of his holding, leaving Millennium Management with 2.02 million TXMD shares at the end of September, while Peter Kolchinsky reduced his exposure by 10%. His fund, RA Capital Management, holds roughly 1.52 million shares worth $8.90 million, according to its latest 13F filing.

Disclosure: none.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading...